See more : Mister Car Wash, Inc. (MCW) Income Statement Analysis – Financial Results
Complete financial analysis of Bruker Corporation (BRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bruker Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Logic Instrument S.A. (ALLOG.PA) Income Statement Analysis – Financial Results
- Richa Industries Limited (RICHAIND.BO) Income Statement Analysis – Financial Results
- Backblaze, Inc. (BLZE) Income Statement Analysis – Financial Results
- BrightSpire Capital, Inc. (BRSP) Income Statement Analysis – Financial Results
- BlackRock Smaller Companies Trust plc (BRSC.L) Income Statement Analysis – Financial Results
Bruker Corporation (BRKR)
About Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.96B | 2.53B | 2.42B | 1.99B | 2.07B | 1.90B | 1.77B | 1.61B | 1.62B | 1.81B | 1.84B | 1.79B | 1.65B | 1.30B | 1.11B | 1.11B | 547.58M | 435.83M | 297.57M | 284.42M | 260.68M | 116.37M | 92.69M | 76.60M | 64.69M | 42.21M |
| Cost of Revenue | 1.45B | 1.23B | 1.21B | 1.05B | 1.08B | 995.60M | 952.90M | 868.80M | 915.20M | 1.05B | 1.03B | 960.00M | 899.20M | 698.90M | 595.90M | 602.10M | 294.44M | 236.50M | 171.76M | 165.94M | 144.83M | 55.87M | 43.59M | 35.59M | 28.13M | 0.00 |
| Gross Profit | 1.51B | 1.31B | 1.21B | 939.80M | 995.30M | 900.00M | 813.00M | 742.50M | 708.60M | 763.30M | 805.20M | 831.40M | 752.50M | 606.00M | 518.60M | 505.00M | 253.14M | 199.33M | 125.81M | 118.48M | 115.85M | 60.50M | 49.10M | 41.02M | 36.56M | 42.21M |
| Gross Profit Ratio | 51.05% | 51.59% | 50.03% | 47.29% | 48.02% | 47.48% | 46.04% | 46.08% | 43.64% | 42.20% | 43.78% | 46.41% | 45.56% | 46.44% | 46.53% | 45.61% | 46.23% | 45.74% | 42.28% | 41.66% | 44.44% | 51.99% | 52.97% | 53.54% | 56.51% | 100.00% |
| Research & Development | 294.80M | 235.90M | 220.80M | 198.00M | 187.70M | 173.40M | 162.70M | 149.00M | 145.70M | 174.20M | 190.50M | 195.30M | 177.20M | 141.40M | 126.40M | 133.80M | 58.47M | 49.96M | 41.36M | 43.22M | 38.03M | 20.73M | 18.47M | 20.03M | 15.14M | 0.00 |
| General & Administrative | 730.10M | 610.80M | 564.50M | 477.80M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 406.60M | 303.10M | 69.50M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
| Selling & Marketing | 0.00 | -3.40M | -3.30M | -9.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00M | -5.80M | 185.80M | 183.80M | 105.98M | 84.01M | 51.44M | 55.98M | 60.42M | 26.81M | 21.71M | 0.00 | 0.00 | 0.00 |
| SG&A | 730.10M | 607.40M | 561.20M | 468.60M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 403.60M | 297.30M | 255.30M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
| Other Expenses | 52.20M | -29.70M | -14.30M | -24.90M | -6.50M | -19.50M | -19.70M | -25.80M | -20.40M | -21.20M | -28.60M | -13.90M | 13.10M | 5.80M | 200.00K | 8.50M | 4.66M | 5.72M | 0.00 | 0.00 | 9.75M | 202.00K | -356.00K | 0.00 | 3.49M | 42.37M |
| Operating Expenses | 1.08B | 843.30M | 782.00M | 666.60M | 687.90M | 618.10M | 578.60M | 539.50M | 537.90M | 625.20M | 628.40M | 637.70M | 596.90M | 450.30M | 255.30M | 388.30M | 198.51M | 162.95M | 115.17M | 119.59M | 125.53M | 54.75M | 45.83M | 40.28M | 33.38M | 42.37M |
| Cost & Expenses | 2.53B | 2.07B | 1.99B | 1.71B | 1.77B | 1.61B | 1.53B | 1.41B | 1.45B | 1.67B | 1.66B | 1.60B | 1.50B | 1.15B | 851.20M | 990.40M | 492.95M | 399.45M | 286.93M | 285.53M | 270.36M | 110.62M | 89.42M | 75.87M | 61.51M | 42.37M |
| Interest Income | 11.20M | 4.10M | 900.00K | 3.20M | 1.30M | 1.20M | 800.00K | 300.00K | 1.20M | 800.00K | 1.00M | 900.00K | 1.00M | 900.00K | 1.00M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.40M | 16.10M | 14.30M | 14.40M | 16.00M | 12.60M | 15.40M | 13.20M | 13.00M | 13.30M | 13.40M | 14.30M | 7.30M | 5.60M | 7.50M | 40.50M | 11.84M | 3.96M | 0.00 | 3.85M | 6.36M | 20.15M | 0.00 | 0.00 | 1.35M | 0.00 |
| Depreciation & Amortization | 114.90M | 88.80M | 89.20M | 80.50M | 75.60M | 64.90M | 63.90M | 54.30M | 53.30M | 59.70M | 61.30M | 59.10M | 3.00M | 5.80M | 29.70M | 29.90M | 12.63M | 13.29M | 8.61M | 9.79M | 16.87M | 8.20M | 6.04M | 4.15M | 3.49M | 0.00 |
| EBITDA | 599.00M | 545.30M | 497.10M | 320.70M | 380.00M | 340.10M | 299.50M | 262.10M | 235.90M | 215.60M | 239.10M | 211.70M | 205.70M | 155.70M | 166.30M | 134.80M | 63.07M | 49.87M | 19.25M | 8.68M | 697.00K | 17.47M | 10.30M | 4.88M | 6.66M | -161.00K |
| EBITDA Ratio | 20.21% | 21.75% | 21.37% | 17.79% | 18.48% | 18.29% | 16.89% | 15.97% | 14.08% | 11.57% | 12.94% | 12.14% | 9.60% | 12.38% | 35.67% | 14.75% | 13.29% | 11.85% | 6.47% | 3.05% | 5.91% | 20.80% | 9.68% | 6.64% | 10.93% | -0.38% |
| Operating Income | 436.90M | 432.70M | 413.30M | 248.30M | 300.90M | 262.40M | 214.70M | 177.20M | 145.70M | 105.40M | 148.20M | 156.00M | 155.60M | 155.70M | 136.70M | 108.20M | 49.97M | 30.66M | 10.64M | -1.12M | -9.68M | 5.75M | 3.27M | 734.00K | 3.18M | -161.00K |
| Operating Income Ratio | 14.74% | 17.10% | 17.09% | 12.49% | 14.52% | 13.84% | 12.16% | 11.00% | 8.97% | 5.83% | 8.06% | 8.71% | 9.42% | 11.93% | 12.27% | 9.77% | 9.13% | 7.04% | 3.57% | -0.39% | -3.71% | 4.94% | 3.53% | 0.96% | 4.91% | -0.38% |
| Total Other Income/Expenses | 107.30M | -18.80M | -19.70M | -22.50M | -20.50M | -17.70M | -21.70M | -4.20M | -17.70M | -4.10M | -23.60M | -17.70M | -10.10M | -5.60M | -7.60M | -15.00M | -89.09M | 3.76M | -780.00K | -3.78M | 1.85M | -9.88M | 2.73M | 1.59M | -1.32M | 161.00K |
| Income Before Tax | 544.20M | 413.90M | 393.60M | 225.80M | 280.40M | 244.70M | 197.80M | 177.60M | 128.00M | 101.30M | 124.60M | 138.30M | 145.50M | 150.10M | 129.10M | 93.20M | 48.61M | 34.42M | 11.95M | -4.90M | -7.83M | -4.14M | 6.01M | 2.32M | 1.86M | 0.00 |
| Income Before Tax Ratio | 18.36% | 16.36% | 16.28% | 11.36% | 13.53% | 12.91% | 11.20% | 11.02% | 7.88% | 5.60% | 6.77% | 7.72% | 8.81% | 11.50% | 11.58% | 8.42% | 8.88% | 7.90% | 4.02% | -1.72% | -3.00% | -3.56% | 6.48% | 3.03% | 2.88% | 0.00% |
| Income Tax Expense | 117.70M | 116.40M | 113.00M | 64.40M | 82.40M | 63.70M | 117.50M | 23.10M | 23.10M | 41.70M | 42.80M | 60.10M | 51.50M | 53.30M | 48.10M | 28.00M | 16.78M | 15.93M | 8.26M | 2.87M | 9.72M | 2.06M | 2.37M | 254.00K | 986.89K | 0.00 |
| Net Income | 427.20M | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M | 78.60M | 153.60M | 101.60M | 56.70M | 80.10M | 77.50M | 92.30M | 95.40M | 81.20M | 64.90M | 31.53M | 18.48M | 3.65M | -7.83M | -17.55M | -6.20M | 3.64M | 2.25M | 1.25M | 0.00 |
| Net Income Ratio | 14.41% | 11.72% | 11.46% | 7.94% | 9.51% | 9.48% | 4.45% | 9.53% | 6.26% | 3.13% | 4.35% | 4.33% | 5.59% | 7.31% | 7.29% | 5.86% | 5.76% | 4.24% | 1.23% | -2.75% | -6.73% | -5.33% | 3.92% | 2.94% | 1.93% | 0.00% |
| EPS | 2.92 | 2.00 | 1.83 | 1.03 | 1.27 | 1.15 | 0.50 | 0.95 | 0.60 | 0.34 | 0.48 | 0.47 | 0.56 | 0.58 | 0.50 | 0.40 | 0.61 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
| EPS Diluted | 2.90 | 1.99 | 1.81 | 1.02 | 1.26 | 1.14 | 0.49 | 0.95 | 0.60 | 0.33 | 0.48 | 0.46 | 0.55 | 0.58 | 0.49 | 0.39 | 0.60 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
| Weighted Avg Shares Out | 146.40M | 148.60M | 151.40M | 153.40M | 155.20M | 156.20M | 158.10M | 161.40M | 168.20M | 167.80M | 166.50M | 166.00M | 165.40M | 164.40M | 163.50M | 162.70M | 161.20M | 101.51M | 100.82M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
| Weighted Avg Shares Out (Dil) | 147.20M | 149.40M | 152.90M | 154.60M | 156.60M | 157.20M | 159.10M | 162.20M | 169.10M | 169.50M | 168.50M | 167.40M | 166.90M | 165.70M | 164.90M | 165.60M | 164.30M | 102.56M | 101.13M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
Cellens Announces Collaboration with Bruker BioAFM to Advance Mechanobiology Technology for Cancer Detection
Bruker (BRKR) Launches neofleX MALDI-TOF/TOF MSI System
Bruker Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics
Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications
Bruker Applied Mass Spectrometry Division Showcases High-Performance Solutions for Research and Analysis in Applied Laboratories
Bruker Corporation to Present at Upcoming Investor Conferences
Bruker Announces Pricing of Public Offering of Common Stock
Bruker Announces Public Offering of Common Stock
Bruker (BRKR) Gains Market Share on Innovation Amid Macro Woes
Peeling Back The Layers: Exploring Bruker Through Analyst Insights
Source: https://incomestatements.info
Category: Stock Reports